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S U M M A R Y
Objectives: We analysed the distribution of vaccine and non-vaccine Streptococcus pneumoniae serotypes
and the antimicrobial susceptibility of pneumococcal strains isolated from healthy Romanian children.
Methods: A multi-centre cross-sectional study was performed in four counties to evaluate carried strains
of S. pneumoniae isolated from 2000 children aged 0–5 years.
Results: S. pneumoniae carriage was detected in 25.25% of the tested children. Carriage increased from
16.7% among infants to 29.4% in 3–5-year-old children (p < 0.0001). The proportions of the serotypes
included in pneumococcal conjugate vaccines PCV7, PCV10, and PCV13 among our isolates were 39.9%,
40.1%, and 58.7%, respectively. Erythromycin resistance was 72.5%, and it was signiﬁcantly lower in non-
vaccine serotypes compared with PCV13 serotypes: 57.3% versus 83.6% (p < 107). Penicillin minimum
inhibitory concentrations (MICs) >0.064 mg/l were recorded in 71.6%, but the penicillin MIC was >2 mg/
l for only 8.4% of tested isolates.
Conclusions: In Romanian children, the majority of carried S. pneumoniae isolates are vaccine serotypes.
The isolates with MICs deﬁning macrolide resistance were very frequent, as well as the isolates with
MICs deﬁning penicillin resistance in the case of meningitis or penicillin dose-dependent susceptibility
for other infections, mainly for the strains belonging to PCV13 serotypes. The implementation of PCV13
within the Romanian national immunization programme could reduce the circulation of these strains
with higher macrolide and/or penicillin MICs.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Pneumococcal conjugate vaccines (PCV) represent a major
medical advance, reducing the morbidity and mortality of invasive
pneumococcal disease (IPD), community-acquired pneumonia, and
acute otitis media caused by serotypes included in these vaccines.1
However, the successful durability of a national immunization* Corresponding author. Tel.: +40 21 3186100/4128.
E-mail address: araﬁla@yahoo.com (A. Raﬁla).
http://dx.doi.org/10.1016/j.ijid.2014.08.020
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).programme may be inﬂuenced by the emergence of non-vaccine
serotypes after the implementation of vaccination.2,3
Streptococcus pneumoniae colonizes the nasopharynx, particu-
larly in young children, where it serves as a reservoir for person-to-
person transmission.4,5
The distribution of S. pneumoniae serotypes is not the same in
patients with pneumococcal diseases compared with healthy
colonized people, most likely due to the different invasive
capacities of the serotypes.6,7 Studies conducted in different
countries indicate a signiﬁcant decrease in the carriage of vaccine-
related strains after the inclusion of PCV in the national
immunization programme.3ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Streptococcus pneumoniae carriage rate according to the age group
Age group (n) Carriers, n (%) Carriage rate 95% CI
0–11 months (186) 31 (16.7) 12.0–22.7
12–35 months (751) 162 (21.6) 18.8–24.5
36–60 months (1063) 312 (29.4) 26.7–32.2
Total 505 (25.3) 23.4–27.2
CI, conﬁdence interval.
Table 2
Serotype distribution in the three age groups: 0–11, 12–35, and 36–60 months
Serotype 0–11 months
(n = 29), n
12–35 months
(n = 141), n
36–60 months
(n = 283), n
Total
(n = 453),
n (%)
6A 3 14 34 51 (11.2)
6B 6 19 35 60 (13.2)
6 non-A, non-B 1 10 26 37 (8.2)
14 1 10 14 25 (5.5)
15 3 12 16 31 (6.8)
19A 4 10 17 31 (6.8)
19F 6 32 54 92 (20.3)
19 non-A, non-F 1 6 26 33 (7.3)
23F 1 5 11 17 (3.8)
23 non-F 0 7 23 30 (6.6)
Other PCVa 1 0 4 5 (1.1)
Other non-PCVb 2 16 22 39 (8.6)
PCV, pneumococcal conjugate vaccine.
a Other PCV serotypes: 9 V, 18C.
b Other non-PCV serotypes: 3, 5, 7, 8, 9 non-V, 10, 11, 12, 17, 18 non-C, 20, 22.
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epidemiological studies are needed to determine the magnitude of
this alarming problem. Most of the available data have analysed
the susceptibility of S. pneumoniae to two of the most common
antibiotics used for pneumococcal diseases: penicillin and
erythromycin.8,9
PCVs will be introduced for the ﬁrst time into the routine
Romanian childhood immunization schedule in 2014. There is a
scarcity of data regarding the S. pneumoniae serotypes involved in
IPD in different areas of Romania. Moreover, although limited, the
information regarding S. pneumoniae carriage in children in
Romania indicates high antibiotic resistance rates.10
Therefore, we designed a national, multi-centre, cross-sectional
observational study to assess S. pneumoniae carriage and the
serotype distribution in healthy children before the large-scale
implementation of PCV immunization in Romania. In addition,
penicillin and macrolide S. pneumoniae susceptibility rates were
determined.
2. Methods
2.1. Setting and study design
This prospective, multi-centre, cross-sectional observational
study was conducted from November 2011 to April 2013 in four
different locations: Bucharest, Iasi, Constanta, and Targu Mures.
Children aged 0–60 months old were enrolled. They were
selected from two types of location: paediatric ambulatory care
clinics (n = 500) and nurseries and school gardens (n = 1500);
10 locations in Bucharest and two locations in the other three
centres (a maximum of ﬁve children included from each class)
were selected.
Only immune-competent children were considered eligible.
Children with acute respiratory tract infections at the time of
enrolment or who had received antibiotic treatment within
10 days of the time of enrolment were excluded. Only one
nasopharyngeal swab was taken from each participant. Written
informed consent was obtained from a parent/tutor of each child
prior to enrolment. Two thousand children were enrolled from
2763 eligible children. The number of tested children from
participating centres was 1413 in Bucharest, 217 in Iasi, 167 in
Targu Mures, and 203 in Constanta.
The ethics committee of each participating institution approved
the study protocol.
2.2. Sampling
A nasopharyngeal sample was obtained using a ﬂexible wire
with Dacron/Rayon tip. The swabs were inoculated into MW173
Amies transport medium (Transwab; Medical Wire and Equip-
ment, Potley, UK) and all were processed within 16 h at local
clinical microbiology laboratories.
2.3. S. pneumoniae isolation and identiﬁcation
The S. pneumoniae isolates were ﬁrst identiﬁed by local
microbiology laboratories. For the isolation of S. pneumoniae,
swabs were inoculated onto Colombia agar with 5% sheep blood
and 5.0 mg/ml gentamicin and were incubated aerobically at 35 8C
for 48 h. S. pneumoniae was identiﬁed by colony morphology, a-
haemolysis, and inhibition by optochin. The isolates were stored at
20 8C/80 8C and sent to the central laboratory for conﬁrmation
of identiﬁcation, which was based on haemolysis on agar with 5%
sheep blood (Oxoid Ltd, Hants, UK) at 37 8C with 5% CO2 and
growth inhibition by optochin (Oxoid Ltd).The susceptibility of S. pneumoniae to penicillin and macrolide
was determined by European Committee on Antimicrobial
Susceptibility Testing (EUCAST) standardized disk diffusion
method on Mueller–Hinton agar with 5% blood (Oxoid Ltd) with
an erythromycin disk of 15 mg and an oxacillin disk of 10 mg
(Oxoid Ltd). If the diameter of the oxacillin inhibition zone was less
than 20 mm, penicillin minimum inhibitory concentrations (MICs)
were determined by Etest (bioMe´rieux, Marcy l’Etoile, France). A
strain was considered fully susceptible to penicillin when the
penicillin MIC was 0.064 mg/l and resistant if the MIC was
>2 mg/l. Erythromycin resistance was deﬁned as a growth
inhibition zone smaller than 22 mm. Serotyping was performed
with type and pooled antisera (Statens Serum Institut, Copenha-
gen, Denmark) using the chessboard method, in accordance with
the manufacturer’s recommendations. The tested serotypes were
1, 3, 4, 5, 6, 6A, 6B, 7, 7F, 8, 9, 9 V, 10, 11, 12, 14, 15, 17, 18, 18C, 19,
19A, 19F, 20, 22, 23, and 23F.
2.4. Statistical analysis
We assumed a similar birth rate in the last 6 years to
standardize the unequal distribution of patients in the age groups.
The statistical analysis of categorical variables was performed by
Chi-square test and Fisher’s exact test, using Epi Info 7 software (US
CentersforDiseaseControlandPrevention(CDC),Atlanta,GA,USA).A
two-sided p-value of <0.05 was considered statistically signiﬁcant.
In the sub-analysis, where carrier rate, serotype distribution,
and antibiotic resistance were described by age group, we divided
age into three groups: 0–11 months (infancy), 12–35 months
(young toddlers), and 36–60 months (older toddlers). The relative
risk (RR) and 95% conﬁdence interval (CI) were calculated to
estimate the S. pneumoniae carriage for each group.
3. Results
Two thousand children were enrolled in the study. The
distribution among the three age groups 0–11, 12–35, and 36–
60 months was 9.3%, 37.5%, and 53.1%, respectively.
Table 3
Serotype distribution related to PCV serotypes (number (percentage) and 95% conﬁdence interval)
Serotypes included in vaccine NVTa
PCV7 PCV10 PCV13
0–11 months (n = 31) 15 (48.4%)
32.0–65.2
15 (48.4%)
32.0–65.2
23 (74.2%) 56.7–86.3 8 (25.8%) 13.7–43.3
12–35 months (n = 162) 66 (40.7%)
33.5–48.4
68 (41.9%)
34.6–49.7
93 (57.4%)
49.7–64.8
69 (42.6%) 35.2–50.3
36–60 months (n = 312) 118 (37.8%) 32.6–43.3 118 (37.8%)
32.6–43.3
174 (55.7%)
50.2–61.2
138 (44.3%) 38.8–49.8
Total (n = 505) 199 (39.4%) 35.2–43.7 201 (39.8%) 35.6–44.1 290 (57.4%)
53.1–61.7
215 (42.6%)
38.3–46.9
PCV, pneumococcal conjugate vaccine.
a NVT: serotypes not included in the PCV13 vaccine or non-typeable S. pneumoniae.
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representing 25.25% of all children (95% CI 23.39–27.20%). The
carriage rate increased signiﬁcantly with age, from 16.7% in the 0–
11 months group to 29.4% in the children aged 36–60 months
(Table 1), with a Cramer’s V = 0.105 and p < 0.0001.
In children older than 36 months of age, the risk of
pneumococcal colonization was higher compared to children aged
younger than 36 months (RR 1.42, 95% CI 1.22–1.67, p < 0.00001).
Overall, the S. pneumoniae serotype was identiﬁed in 453
(89.7%) of the 505 isolates. The most frequently identiﬁed
serotypes were 19F (92 strains; 20.3%), 6B (60 strains; 13.2%),
and 6A (51 strains; 11.2%). In infants, serotypes 6B and 19F were
the most prevalent (six isolates each; 20.6%). In the other age
groups, 19F was dominant (32 strains (22.6%) and 54 strains (19%),
respectively) (Table 2).
Of all isolates, a proportion of 39.4% were serotypes included in
PCV7 and 57.8% were serotypes included in PCV13 (Table 3).
Standardized with age distribution, the coverage was 39.9% PCV7,
40.1% PCV10, and 58.7% PCV13. The relative risk for the carriage of
a serotype included in PCV13 compared to PCV10 and PCV7 was
1.45 (95% CI 1.27–1.66; p < 0.0001) and 1.47 (95% CI 1.29–1.67;
p < 0.0001), respectively.
The vaccine serotypes were more frequently detected in infants
than in children older than 3 years, both for PCV7 serotypes (48.4%
versus 37.8%, p = 0.25), and for PCV13 serotypes (74.2% versus
55.7%, RR 1.33 (95% CI 1.06–1.67), p = 0.05) (Table 3).
Erythromycin resistance was detected in 72.5% of the isolates
(95% CI 68.4–76.2%). Serotypes included in the PCVs showed
signiﬁcantly higher resistance rates to macrolides than non-PCV
serotypes: 85.9% PCV7 and 83.6% PCV13 versus 57.3% for non-
vaccine serotypes (NVT) (RR PCV7 vs. NVT = 1.50 (95% CI 1.32–
1.71), p < 107, and RR PCV13 vs. NVT = 1.46 (95% CI 1.29–1.66),
p < 0.001) (Table 4).
Macrolide resistance of PCV13 vaccine serotype isolates of
S. pneumoniae increased with age, from 78.3% (0–1 years old) toTable 4
Streptococcus pneumoniae isolates with an erythromycin inhibition diameter less than 
interval)
Serotypes vaccine-included 
PCV7 PCV13
0–11 months
(n = 31)
13/15 (86.7%) 62.1–96.3 18/23 (78.3%) 58.1–
12–35 months
(n = 162)
55/66 (83.3%) 72.6–90.4 77/95 (81.1%)
72–87.7
36–60 months
(n = 312)
103/118 (87.3%)
80.1–92.1
149/174 (85.6%)
79.6–90.1
0–5 years
(n = 505)
171/199 (85.9%) 80.4–90.1 244/292 (83.6%) 78.9–
PCV, pneumococcal conjugate vaccine.
a NVT: serotypes not included in the PCV13 vaccine or non-typeable S. pneumoniae.81.1% (1–3 years old) and 85.6% (3–5 years old) (R2 = 0.48), but not
for PCV7 and NVT serotypes (Table 4).
In 115 of the 404 strains tested (28.4%), the penicillin MIC was
0.064 mg/l; 86 of these isolates were NVT (74.8%). A penicillin
MIC >2 mg/l was found for 34 of the 404 tested isolates (8.4%). The
isolates with MICs deﬁning penicillin resistance in the case of
meningitis or penicillin dose-dependent susceptibility for other
infections, were very frequent. A penicillin MIC >2 mg/l was more
common in the serotypes included in PCV7 (13.1%) than in all of the
PCV13 serotypes (9.5%) or non-PCV13 serotypes (6.9%), but the
difference did not reach statistical signiﬁcance (p = 0.25 and
p = 0.08, respectively) (Table 5).
4. Discussion
Streptococcus pneumoniae carriage in children, reported in
recent studies from different countries, is as high as 38% (Czech
Republic), 42% (Israel), 51% (UK), and even 68% (Kenya).2,11–13 A
previous report from central Romania also indicated a high
carriage rate of 51%.10 Our study shows a lower rate of carriage of
25.3%. Among recently published papers, only one Italian study
performed in non-winter months reported a very low carriage rate,
8.6%, which could be attributed to the selection of healthy children,
genetic factors, and potentially a lower sensitivity of the study
methods used.14
In the present study, 58.7% of the carried strains belonged to
PCV13 vaccine serotypes, which was signiﬁcantly higher than for
serotypes included in PCV7 and PCV10. Similar data have been
reported from the UK, where the carriage rate of vaccine serotypes
during the period before PCV use in routine immunization was
62%.15 In this British study, the PCV coverage rate was 70% in
children aged 0–2 years and less than 55% in older children.
According to our data, the impact that PCV13 could have on the
incidence of S. pneumoniae nasopharyngeal carriage would be
greatest in infants. A possible explanation for the decreasingthat deﬁned for susceptibility (22 mm) (number (percentage) and 95% conﬁdence
NVTa Total
90.3 3/8 21/31 (67.7%) 50.1–81.4
41/67 (61.2%)
49.2–71.9
118/162 (72.8%) 65.5–79.1
78/138 (56.5%)
48.2–64.5
227/312 (72.7%)
67.6–77.4
87.4 122/213 (57.3%) 50.6–63.7 366/505 (72.5%)
68.4–76.2
Table 5
Penicillin MIC results for Streptococcus pneumoniae isolates (number (percentage)
and 95% conﬁdence interval)
MIC for penicillin
(serotypes included in)
<0.06 mg/l 0.06–2 mg/l >2 mg/l
PCV7 (n = 160) 17 (10.6%)
6.7–16.4
122 (76.3%)
69.1–82.2
21 (13.1%)
8.7–19.2
PCV13 (n = 231) 29 (12.6%)
8.9–17.4
180 (77.9%)
72.2–82.8
22 (9.5%)
6.4–14
Non-VT (n = 173) 86 (49.7%)
42.3–57.1
75 (43.4%)
36.2–50.8
12 (6.9%)
4.0–11.7
Total (n = 404) 115 (28.5%)
24.3–33.1
255 (63.1%)
58.3–67.7
34 (8.4%)
6.1–11.5
MIC, minimum inhibitory concentration; PCV, pneumococcal conjugate vaccine;
VT, vaccine included serotype.
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interactions with people carrying non-vaccine serotypes (i.e.,
people from neighbouring regions, such as Moldova or Hungary,
where vaccination is mandatory and non-vaccine serotypes have
probably emerged). This study could be a baseline for future cross-
sectional studies aimed at monitoring changes in the serotype
carriage prevalence in the same population.
Another important aspect of our study is the analysis of
antimicrobial resistance. The rate of macrolide resistance was
found to be 78.3% in infants and 85.6% in the 36–60 months age
group, which is higher than rates reported in all other European
countries.16,17 A few other studies from Asia have indicated a
similar level of macrolide resistance: over 70% in carriage isolates
from a region in Japan, and 80–96% in isolates from patients with
pneumococcal infections in China, Taiwan, and Vietnam.18,19 A
study from Israel revealed a similar level of resistance in children,
most likely in an area with a similar over-prescription of antibiotics
in children.20 This level of resistance could be the result of the
signiﬁcant overuse of macrolides in children. A further analysis of
antibiotic usage in children in Romania is necessary to determine
whether macrolide prescription in children needs to be restricted.
The higher resistance rates among PCV serotypes is another reason
to include PCV in the national immunization programme in
Romania, to protect children against the most resistant serotypes
of S. pneumoniae.
It is important to emphasize that there are different suscepti-
bility cut-offs for penicillin for meningitis and for other pneumo-
coccal diseases (i.e., pneumonia, acute otitis media). Analysing S.
pneumoniae isolates from carriage studies should use these
different cut-offs because these isolates can serve as an indicator
of the different S. pneumoniae-related diseases. The proportion of
isolates with a penicillin MIC >2 mg/l (resistant strains for clinical
isolates whatever the type of infection, meningitis or non-
meningeal infection) was very low compared to the macrolide
resistance rate, similar to Romanian data for invasive pneumococ-
cal infections reported to the European Antimicrobial Resistance
Surveillance Network (EARS-Net) in recent years.21 However,
almost 70% of strains had a MIC >0.06 mg/l, the cut-off value
deﬁning resistance for meningeal isolates and penicillin reduced
susceptibility for other isolates. In our study, the proportion of
penicillin with reduced susceptibility and the macrolide-resistant
isolate rates were extremely high, similar to previous reports from
central and north-eastern Romania,10,22 and the resistance rates
among NVT serotypes were lower. The introduction of PCV13 into
the Romanian national immunization programme will decrease
the circulation of the vaccine serotypes and will allow the use of a
narrower spectrum antibiotic for the treatment of S. pneumoniae
infections in children.
One limitation of our study is the underrepresentation of
infants compared to 1–5-year-old children. Additionally, studies in
other regions of Romania are needed to develop a betterunderstanding of the magnitude of antibiotic resistance in our
country. Nevertheless, the extremely high resistance rates found in
this study, especially for macrolides, require that this problem be
addressed by an intervention in antibiotic usage in children in
Romania; the implementation of national pneumococcal immuni-
zation could also be helpful.
In conclusion, more than half of the S. pneumoniae strains
isolated from Romanian children belonged to PCV13 serotypes.
Macrolide resistance and penicillin diminished susceptibility rates
among S. pneumoniae isolates were found to be extremely high and
greater among vaccine serotypes. The introduction of PCV13 into
the Romanian national immunization programme might reduce
the number of invasive pneumococcal infections and the risk of
infection with multiple drug-resistant S. pneumoniae.
Our study provides benchmark data for the further analysis of
the carriage rates of different S. pneumoniae serotypes and
antibiotic resistance dynamics after the implementation of PCV
within the Romanian national immunization programme.
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